The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...

Elevated Levels of HBV DNA and HBsAg May Increase Liver Cancer Risk

HealthDay News — Elevated levels of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) are associated with increased risks of liver cancer, according to a study published in the Journal of Gastroenterology and Hepatology. The researchers found that the risk of liver cancer was positively associated with increasing levels of HBV DNA and HBsAg in dose-response manners.The adjusted odds ratios [ORs] increased from 2.11 to 10.47  for those wi

Association Between HBV, HCV and Age-Related Cataracts

According to research in Scientific Reports, the occurrence of age-related cataracts is associated with hepatitis B virus (HBV) and hepatitis C virus C (HCV) infection. Liver dysfunction is a known significant risk factor for cataract formation, and the liver-damaging effects of HBV and HCV are hypothesised to play a role as well. To test this, associations between hepatitis and cataracts were tested along with any mediation of these associations by the l

US: ACP and CDC issue recommendations for hepatitis B screening, vaccination, and care

Philadelphia, Nov. 21, 2017 -- Reducing chronic hepatitis B infections by screening at-risk adults, increasing hepatitis B vaccination rates, and linking infected persons to care is a public health priority, the American College of Physicians (ACP) and the Centers for Disease Control and Prevention (CDC) advise in a new paper published today in Annals of Internal Medicine. "The majority of persons at risk for or infected with the hepatitis B virus do no

Mongolia’s liver cancer crisis: ‘No other country has a problem like this’

Cirrhosis and liver cancer cause 15% of all deaths in Mongolia. Now the government is waking up to the issue – and tackling the hepatitis that triggers it. Danzan Purev beams as he shows members of a support group photos of his infant nephew on his iPhone. The 68-year-old geologist is charismatic and jokes with the others gathered in the room in Ulan Bator. But his mood changes as he begins to recount his long experience with hepatitis, a disease that has

Benitec and Biotron in the race for $3.5b Hepatitis B market

Chronic Hepatitis B, a currently incurable disease, is attracting growing attention among international biotechs. The World Health Organisation estimates 257 million people live with Hep B and up to 900,000 die each year from related diseases such as liver cancer and cirrhosis. In Australia, more than 232,000 people have chronic hepatitis B, according to lobby group Hepatitis Australia. “Deaths from primary liver cancer have been climbing faster tha

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has announced that its vaccine candidate, TG1050, has demonstrated good efficacy

The Week in Review: September 29 – October 6, 2017

Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease.  The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...

Liver cancer remains a leading cause of cancer-related mortality worldwide

Primary liver cancer incidence increased by 75% between 1990 and 2015, and the disease remains one of the leading causes of cancer death in the world, according to a report from the Global Burden of Diseases Study 2015. Further, hepatitis B virus was the leading cause of new cases of liver cancer in 2015, the research showed. The highest rates of liver cancer incidence, disability-adjusted life-years and mortality occurred in East Asia. Japan had 75% o

Vivek Ramaswamy’s Roivant backs Arbutus’ hepatitis B program

With hepatitis C virus starting to look like a conquered foe, attention is turning to the fight against chronic hepatitis B virus (HBV), and Vivek Ramaswamy’s Roivant has just put another sizable block of cash behind a program in development at Canada’s Arbutus Biopharma. The $116 million share purchase deal comes on the heels of positive phase 2 data for Arbutus’ lead HBV candidate ARB-1467, which suggest the gene-silencing drug can further reduce hepati